HDAC-IN-32 is a highly effective HDAC inhibitor presenting IC50 values of 5.2, 11, and 28 nM for HDAC1, HDAC2, and HDAC6, respectively. This compound demonstrates notable anti-proliferative properties against tumor cells, as well as significant in vivo antitumor efficacy, which can elicit antitumor immunity [1].

HDAC-IN-32 (compound 9k) induces upregulation of Ac-HH3 and Ac-tubulin in tumor cells and induces apoptosis by cleavage of caspase-3. HDAC-IN-32 induces downregulation of SSRP1 and SPT16 and leads to chromatin damage. HDAC-IN-32 possesses better antimigration activities than SAHA and could reduce the expression level of MMP-2, which plays critical roles in tumor migration [1].